Clinical trial
The Effectiveness and Safety of Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT03964753 is registered in ClinicalTrials.gov with Hebei Medical University Fourth Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effectiveness and Safety of Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma
- Lead sponsor
- Hebei Medical University Fourth Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 24, 2019
- Completion date
- December 24, 2026
- Enrollment
- 202 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.